RePORT: C-TRIUMPH: Nested Study on Association of Lipid Mediators of Inflammation with TB Treatment Outcomes

Post Date: 
2017-08-03
   |   
Clinical Sites: 
   |   
Countries: 
Summary: 

Recent studies have shown the significant role that host lipids play in modulating immunity and disease outcomes. Prostaglandins and leukotrienes are lipids that have a pro-inflammatory role in the fight against infectious agents while Specialized Pro-resolving lipid Mediators (SPMs) including resolvins, protectins and maresins, are important for the effective resolution of inflammation(1-3). In TB, there is evidence of a delicate balance where an excess of either the pro-inflammatory LTB4 or pro-resolving LXA4 can result in impaired host response to Mycobacterium tuberculosis (Mtb)(4-7). The purpose of this study is to identify host biomarkers associated with TB treatment responses by assessing the plasma lipidome.

Design:

In this study, we will assess whether the baseline and early treatment levels and balance of various pro-inflammatory and pro-resolving lipid mediators can predict 1) TB treatment failure and 2) TB recurrence using biobanked samples from a well-characterized cohort of TB cases, funded by the US NIH and Indian government known as the CTRIUMPH RePORT India cohort. Using a longitudinal analysis approach of biobanked samples, we will also assess how these lipid mediators change with treatment and whether the changes are predictive of treatment failure and recurrence. 

Objectives:

  1. Identify lipidome profiles associated with treatment failure or death in adult pulmonary TB patients 
  2. Identify lipidome profiles associated with TB recurrence in cured adult pulmonary TB patients
Collaborators: 

William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK